Today: 26 June 2026
Teradyne stock slides as Nvidia cools chip rally; investors watch March Morgan Stanley conference
26 February 2026
1 min read

Teradyne stock slides as Nvidia cools chip rally; investors watch March Morgan Stanley conference

New York, Feb 26, 2026, 15:27 EST — Regular session

  • Teradyne hit a new high earlier but shares slipped back during the afternoon session.
  • Chip-linked stocks dropped, with investors rethinking the AI trade following Nvidia’s results.
  • A Teradyne officer disclosed a minor planned share sale in a recent regulatory filing.

Teradyne dropped 3.25% to $331.69 Thursday afternoon, after bouncing between $344.92 at its peak and $328.76 at the session low. Volume landed near 3.7 million shares—right around typical levels, according to data. Investing.com

Teradyne’s role as a momentum stand-in for semiconductor test equipment has grown more pronounced. The company’s shares can swing sharply whenever sentiment on AI demand changes, since its gear is what checks chips before they leave the factory.

The mood flipped Thursday. Nvidia’s results just didn’t clear the bar, sending U.S. indexes south. The Philadelphia Semiconductor Index slid 3.6%, dragging down tech-heavy benchmarks. “They did not hit the high end of some people’s expectations,” said Joseph Sroka, chief investment officer at NovaPoint in Atlanta. Reuters

The picture changed on Wednesday. Teradyne jumped 4.17% to finish at $342.82, notching a fresh 52-week high and pulling ahead of rivals like Keysight Technologies, Fortive and Cohu, according to MarketWatch. MarketWatch

Teradyne officer Mills Regan is looking to unload 788 shares, according to a Form 144 filed Wednesday, pegging the total value near $262,000. The filing cites Nov. 25, 2025, as the pre-set date for the trading plan under SEC Rule 10b5-1. Remember, Form 144 simply signals a proposed sale—it doesn’t confirm any shares have traded yet. Teradyne, Inc.

Analysts have scrambled to adjust their targets following the rally. Fintel’s average one-year price target jumped to $308.37, up from $242.09, Nasdaq.com reported late Wednesday. Nasdaq

AI-related demand has fueled the surge. Teradyne, earlier this month, projected first-quarter revenue and profit ahead of Wall Street expectations. “Strong momentum in compute driven by AI,” CEO Greg Smith said, according to Reuters. Reuters

The setup isn’t one-sided. If chipmakers start pulling back on capital expenditures, pause on production ramps, or trim test budgets, orders could take a hit—Teradyne’s stock has hardly behaved like a safe, low-volatility play.

Investors are set to tune in for management’s take on demand and margins, with upcoming appearances such as the Morgan Stanley Technology, Media & Telecom Conference on March 2 listed on Teradyne’s investor calendar. Teradyne, Inc.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Data Providers and Market Information Sources in Financial Reporting
    June 26, 2026, 2:23 PM EDT. This update outlines the key sources of market data used in financial reporting, including ICE Data Services for market information, FactSet for reference data and CUSIP database, the American Bankers Association, Quartr for SEC filings, and TradingView for financial visualization. These providers ensure accurate, timely, and comprehensive data for market analysis and investment decisions, supporting regulatory compliance and transparency in the financial sector.

Latest News

Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

26 June 2026
Eli Lilly surged 6.5% to $1,200.98, adding $65.7 billion in value after the European Medicines Agency’s CHMP backed Jaypirca for leukemia and Medicare announced GLP-1 Bridge coverage for obesity drugs starting July 1, driving a major move in XLV due to Lilly’s 15.84% index weight.
Intel stock slides as chip rally cools — what’s driving INTC today
Previous Story

Intel stock slides as chip rally cools — what’s driving INTC today

Tesla stock falls as California robotaxi permit questions deepen and an insider sale pops up
Next Story

Tesla stock falls as California robotaxi permit questions deepen and an insider sale pops up

Go toTop